Rossari Biotech Ltd.
Fundamentals
- Market cap
- ₹2,963 cr
- P/E
- 19.85×
- ROE
- 11.50%
- Debt / equity
- 0.16
- Div yield
- 0.09%
- 52-week range
- 375.00 — 766.00
Analysis — the numbers vs the call
- Rossari slashes its own margin floor after a quarter that should have settled it
Q1 revenue beat expectations, but management's abrupt guidance reversal on margins and supply exposes a credibility gap.
Company snapshot
Rossari Biotech Ltd.
Chemicals
₹2,875 cr
P/E 19.07×
Latest quarter · Jun 2026
Sales₹697 cr
Net profit₹35 cr
Op. margin+11.6%
EPS₹6.34
Strength & growth
Debt / equity0.31×
Current ratio1.44×
Sales CAGR+53.4%
The timeline — 2 notes on Rossari Biotech Ltd.
July 2026
- 20 Jul 26 · 6:16 PM IST Brief Brief · Earnings · Small cap
Rossari's margin slips to 11.6%, but management says that's the floor.
Q1 revenue rose 28% to ₹697 cr, but EBITDA margin fell 90 bps to 11.6%. The company now sees that as a near-term base and expects B2C exit to add 2-3 ppt.
- 18 Jul 26 · 4:35 PM IST Brief Brief · Earnings · Small cap
Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially
Revenue rose 28% YoY, net profit edged up to ₹351M from ₹336M. Sequential profit fell 24% due to seasonal fluctuations. Board approved trivial ESOP and subsidiary transfer.